Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
CerSci Therapeutics
About
CerSci Therapeutics is poised to deliver a new generation of non-opioid medicines to treat acute and chronic pain.
- 1 - 10
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $1.65M
- Industries
- Biopharma,Biotechnology,Life Science,Neuroscience,Pharmaceutical,Therapeutics
- Founded date
- Feb 1, 2015
- Number Of Employee
- 1 - 10
- Operating Status
- Active
CerSci Therapeutics, a non-opioid drug development firm based in Dallas, Texas, has received approval of their Investigational New Drug (IND) application for CT-044 from the United States Food and Drug Administration (FDA) indicating that its Phase I safety and tolerability clinical trial may proceed (commence phase I dosing June 2019). CT-044, a non-metal based, orally bioavailable, small molecule Radical Species Decomposition Accelerant (RSDAx) of peroxynitrite and hydrogen peroxide, is proposed for the treatment of acute and chronic pain, including acute post-surgical pain and painful diabetic neuropathy.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 31, 2017 | Grant | $1.65M | 1 |
National Institutes of Health
|
— | Detail |
| Mar 8, 2017 | Grant | $225K | 1 |
National Institutes of Health
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Institutes of Health
|
Yes | Grant |
